Article
EC awards Allergan license to market bimatoprost/timolol solution
The European Commission (EC) granted Allergan a license to market bimatoprost/timolol ophthalmic solution (Ganfort) in the European Union. The once-daily combination product is indicated for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension whose disease is insufficiently responsive to topical beta-blockers or prostaglandin analogues.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
